A detailed history of Qube Research & Technologies LTD transactions in Apyx Medical Corp stock. As of the latest transaction made, Qube Research & Technologies LTD holds 285 shares of APYX stock, worth $310. This represents 0.0% of its overall portfolio holdings.

Number of Shares
285
Previous 62,828 99.55%
Holding current value
$310
Previous $85,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$1.26 - $1.66 $78,804 - $103,821
-62,543 Reduced 99.55%
285 $0
Q1 2024

May 14, 2024

SELL
$1.25 - $2.71 $12,240 - $26,536
-9,792 Reduced 13.48%
62,828 $85,000
Q4 2023

Feb 13, 2024

BUY
$1.49 - $3.25 $97,350 - $212,342
65,336 Added 896.98%
72,620 $190,000
Q3 2023

Nov 13, 2023

BUY
$3.07 - $6.2 $22,361 - $45,160
7,284 New
7,284 $23,000
Q3 2022

Nov 14, 2022

BUY
$4.49 - $10.83 $25,337 - $61,113
5,643 Added 21.08%
32,418 $146,000
Q2 2022

Aug 15, 2022

BUY
$3.11 - $7.5 $83,270 - $200,812
26,775 New
26,775 $157,000

Others Institutions Holding APYX

About Apyx Medical Corp


  • Ticker APYX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 34,573,000
  • Market Cap $37.7M
  • Description
  • Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium to cut, coagulate and ab...
More about APYX
Track This Portfolio

Track Qube Research & Technologies LTD Portfolio

Follow Qube Research & Technologies LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.